Targeted radiotherapy firm Actinium Pharmaceuticals (NYSE: ATNM) has announced positive top-line results from the Phase III SIERRA study.
Shares in the company are up more than 70% from last week, with the results showing the trial of its lead product candidate, Iomab-B, met its primary endpoint of durable complete remission in acute myeloid leukemia (AML).
The multicenter study compares Iomab-B as a conditioning regimen prior to a bone marrow transplant (BMT), versus a control arm which allows all current means of conventional care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze